
FILE PHOTO: Research assistants watch sequencing machines analyzing the genetic material of Covid-19 cases at the Wellcome Sanger Institute in Cambridgeshire, England, January 7, 2022
In a statement posted on its website, Pfizer said that it "has not conducted gain of function or directed evolution research," referring to the practice of amplifying a virus' ability to infect humans and the process of selecting 'desirable' traits of a virus to reproduce, respectively.
However, the pharma giant said that it combined the spike proteins of new coronavirus variants with the original strain in order to test its vaccines, and that it created mutations of the virus to test Paxlovid, its antiviral drug.
"In a limited number of cases...such virus may be engineered to enable the assessment of antiviral activity in cells," the company said, adding that this work was carried out in a secure laboratory. The work also sought to create "resistant strains of the virus," it added, describing a process commonly understood as being 'gain of function' research.
Comment: It's gain of function and directed evolution research by other names where the differences are more semantic than practical. See also: